Michigan Legacy Tissue Program

Home Page Our Team For Medical Professionals For Patients Publications Contact Information
  • Rohit Mehra, MD
    Professor, Pathology
    Director, Michigan Legacy Tissue Program

  • Zachary Reichert, MD
    Assistant Professor of Internal Medicine
    Co-Director, Michigan Legacy Tissue Program

    (734) 647-8903

Publications/Impact on Medicine

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.

Cancer Res. 2004 Dec 15;64(24):9209-16.


Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.

Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET.

Prostate. 2006 Feb 15;66(3):248-56.


 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.

Science. 2005 Oct 28;310(5748):644-8.


 Integrative molecular concept modeling of prostate cancer progression.

Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

Nat Genet. 2007 Jan;39(1):41-51. Epub 2006 Dec 17.



Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

Cancer Res. 2008 May 15;68(10):3584-90. doi: 10.1158/0008-5472.CAN-07-6154.



Characterization of bone metastases from rapid autopsies of prostate cancer patients.

Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ.

Clin Cancer Res. 2011 Jun 15;17(12):3924-32. doi: 10.1158/1078-0432.CCR-10-3120. Epub 2011 May 9.



The mutational landscape of lethal castration-resistant prostate cancer.

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA.

Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.

PMID: 22722839


Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.

Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, Pienta KJ, Jiang H, Chinnaiyan AM, Mehra R.

Prostate. 2014 Sep;74(12):1199-208. doi: 10.1002/pros.22836. Epub 2014 Jul 7.

PMID: 25043157


A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.

Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng FY, Chinnaiyan AM.

Neoplasia. 2014 Dec;16(12):1121-7. doi: 10.1016/j.neo.2014.11.006.

PMID: 25499224